IQVIA Holdings Inc (IQV)

In October 2025, IQVIA reported strong third-quarter earnings, beating forecasts and raising guidance due to demand for health data and analytics. In February 2026, the stock declined after a weak full-year profit forecast, despite strong fourth-quarter results. In late January 2026, a collaboration with Boehringer Ingelheim highlighted demand for IQVIA's Technology & Analytics Solutions. In March-April 2026, analyst firms trimmed price targets, reflecting caution around the CRO space, though a "Buy" consensus remained. In March 2026, IQVIA unveiled IQVIA.ai, an AI platform powered by NVIDIA. Geopolitical tensions have also influenced IQVIA's stock performance.

Demand for IQVIA's products and services is driven by long-term trends in the life sciences industry, such as increasing R&D investment and the outsourcing of drug development. While the OTC market can be influenced by factors like inflation and cough/cold seasons, there is no explicit indication of significant seasonality directly impacting IQVIA's core clinical research services, healthcare data and analytics, or contract sales and medical solutions segments. The volatile funding environment for small and mid-sized biotech clients influences demand for Research & Development Solutions.

IQVIA Holdings, Inc. is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare industries. The company operates through three segments: Technology & Analytics Solutions (TAS), which focuses on health information technology and analytics; Research & Development Solutions (R&DS), a contract research organization (CRO) handling clinical trials; and Contract Sales & Medical Solutions (CSMS), offering contract sales and patient engagement services. IQVIA's sector is primarily life sciences, encompassing Contract Research Organization, Pharmaceutical Service, AI, IT, and Consulting.

IQVIA has a significant global presence, with operations in more than 100 countries across the Americas, Europe, Africa, and the Asia-Pacific region.

IQVIA has a strong brand reputation, ranking No. 1 in the Health Care: Pharmacy and Other Services category on the Fortune® World's Most Admired Companies™ list for five consecutive years. The company has faced criticism for collecting and selling anonymized patient medical records but emphasizes its commitment to responsible AI use, privacy, regulatory compliance, and patient safety.

IQVIA's ownership is predominantly institutional, with institutional investors holding approximately 79.56% to over 90% of the company's outstanding shares. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., and Harris Associates L.P. Individual investors hold approximately 19.49% of the stock, while insiders own about 0.96%.